Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 2
2002 5
2003 4
2004 5
2005 3
2006 5
2007 14
2008 13
2009 5
2010 9
2011 19
2012 22
2013 24
2014 35
2015 28
2016 37
2017 35
2018 40
2019 32
2020 46
2021 47
2022 60
2023 48
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

494 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S. Cohen AT, et al. PLoS One. 2015 Dec 30;10(12):e0144856. doi: 10.1371/journal.pone.0144856. eCollection 2015. PLoS One. 2015. PMID: 26716830 Free PMC article. Review.
BACKGROUND: Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indicati …
BACKGROUND: Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thr …
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, Nimri N, Saleem M, Bandyopadhyay D, Krittanawong C, Fadelallah Eljack MM, Tahir MJ, Waqar F. Yasmin F, et al. Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807. Immun Inflamm Dis. 2023. PMID: 36988252 Free PMC article. Review.
This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose including pericarditis/myopericarditis, myocarditis, hypotension, hypertension, arrhythmia, cardiogenic shock, stroke, myocardial infarction/STE …
This study provides an in-depth account of various cardiovascular adverse events reported after the mRNA vaccines' first or second dose incl …
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
Sterne JA, Bodalia PN, Bryden PA, Davies PA, López-López JA, Okoli GN, Thom HH, Caldwell DM, Dias S, Eaton D, Higgins JP, Hollingworth W, Salisbury C, Savović J, Sofat R, Stephens-Boal A, Welton NJ, Hingorani AD. Sterne JA, et al. Health Technol Assess. 2017 Mar;21(9):1-386. doi: 10.3310/hta21090. Health Technol Assess. 2017. PMID: 28279251 Free PMC article. Review.
OBJECTIVE: To determine the best oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and secondary prevention of VTE. ...MAIN OUTCOME MEASURES: Efficacy Stroke, symptomatic VTE, symptomatic deep-vein thrombosis and sympto …
OBJECTIVE: To determine the best oral anticoagulant/s for prevention of stroke in AF and for primary prevention, treatment and …
Catheter-directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute pulmonary embolism.
Harvey JJ, Huang S, Uberoi R. Harvey JJ, et al. Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD013083. doi: 10.1002/14651858.CD013083.pub2. Cochrane Database Syst Rev. 2022. PMID: 35938605 Free PMC article. Review.
BACKGROUND: Acute pulmonary embolism (APE) is a major cause of acute morbidity and mortality. APE results in long-term morbidity in up to 50% of survivors, known as post-pulmonary embolism (post-PE) syndrome. APE can be classified according to the shor …
BACKGROUND: Acute pulmonary embolism (APE) is a major cause of acute morbidity and mortality. APE results in long-term morbidi …
VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.
Fernando SM, Tran A, Cheng W, Sadeghirad B, Arabi YM, Cook DJ, Møller MH, Mehta S, Fowler RA, Burns KEA, Wells PS, Carrier M, Crowther MA, Scales DC, English SW, Kyeremanteng K, Kanji S, Kho ME, Rochwerg B. Fernando SM, et al. Chest. 2022 Feb;161(2):418-428. doi: 10.1016/j.chest.2021.08.050. Epub 2021 Aug 19. Chest. 2022. PMID: 34419428
BACKGROUND: Critically ill adults are at increased risk of VTE, including DVT, and pulmonary embolism. Various agents exist for venous thromboprophylaxis in this population. ...LMWH probably reduces DVT compared with UFH (OR, 0.72 [95% CrI, 0.46-0.98]; moderate cert …
BACKGROUND: Critically ill adults are at increased risk of VTE, including DVT, and pulmonary embolism. Various agents exist fo …
Thromboprophylaxis for trauma patients.
Barrera LM, Perel P, Ker K, Cirocchi R, Farinella E, Morales Uribe CH. Barrera LM, et al. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008303. doi: 10.1002/14651858.CD008303.pub2. Cochrane Database Syst Rev. 2013. PMID: 23543562 Free article. Review.
OBJECTIVES: To assess the effects of thromboprophylaxis in trauma patients on mortality and incidence of deep vein thrombosis and pulmonary embolism. To compare the effects of different thromboprophylaxis interventions and their effects according to the type of trau …
OBJECTIVES: To assess the effects of thromboprophylaxis in trauma patients on mortality and incidence of deep vein thrombosis and pulmona …
Tranexamic Acid in Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.
Dionne JC, Oczkowski SJW, Hunt BJ, Antonelli M, Wijnberge M, Raasveld SJ, Vlaar APJ; for ESICM Transfusion Taskforce and the GUIDE Group. Dionne JC, et al. Crit Care Med. 2022 Mar 1;50(3):e313-e319. doi: 10.1097/CCM.0000000000005362. Crit Care Med. 2022. PMID: 34709209
Extended-use high-dose IV tranexamic acid did not reduce mortality (relative risk, 0.98%; 95% CI, 0.88-1.09; I2 = 63%; high certainty) or bleeding (relative risk, 0.92; 95% CI, 0.82-1.04; p = 0.17 and absolute risk differences, -0.7%; 95% CI, -1.5 to 0.3; high certainty) but resu …
Extended-use high-dose IV tranexamic acid did not reduce mortality (relative risk, 0.98%; 95% CI, 0.88-1.09; I2 = 63%; high certainty) or bl …
Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials.
McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, Camm AJ, Goette A, Zapf A, Alings M, Connolly SJ, Kirchhof P, Lopes RD. McIntyre WF, et al. Circulation. 2024 Mar 26;149(13):981-988. doi: 10.1161/CIRCULATIONAHA.123.067512. Epub 2023 Nov 12. Circulation. 2024. PMID: 37952187
RESULTS: From 785 citations, we identified 2 randomized trials with relevant clinical outcome data: NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes; 2536 participants) evaluated edoxaban, and ARTESiA (Apixaban for the Reductio …
RESULTS: From 785 citations, we identified 2 randomized trials with relevant clinical outcome data: NOAH-AFNET 6 (Non-Vitamin K Antagonist O …
Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Matharu GS, et al. JAMA Intern Med. 2020 Mar 1;180(3):376-384. doi: 10.1001/jamainternmed.2019.6108. JAMA Intern Med. 2020. PMID: 32011647 Free PMC article.
The computer-based searches combined terms and combinations of keywords related to the population (eg, hip replacement, knee replacement, hip arthroplasty, and knee arthroplasty), drug intervention (eg, aspirin, heparin, clexane, dabigatran, rivaroxaban, and warfarin), and outcom …
The computer-based searches combined terms and combinations of keywords related to the population (eg, hip replacement, knee replacement, hi …
Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline 2022.
Hillegass E, Lukaszewicz K, Puthoff M. Hillegass E, et al. Phys Ther. 2022 Aug 4;102(8):pzac057. doi: 10.1093/ptj/pzac057. Phys Ther. 2022. PMID: 35567347
In 2016, the first clinical practice guideline (CPG) addressing the physical therapist management of VTE was published with support by the American Physical Therapy Association's Academy of Cardiovascular and Pulmonary Physical Therapy and Academy of Acute Care, with a pri …
In 2016, the first clinical practice guideline (CPG) addressing the physical therapist management of VTE was published with support by the A …
494 results